- Home
- SCNX vs GOVX Comparison
SCNX vs GOVX Comparison
Compare SCNX & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- GOVX
- Stock Information
- Founded
- SCNX 2010
- GOVX 2001
- Country
- SCNX United States
- GOVX United States
- Employees
- SCNX N/A
- GOVX N/A
- Industry
- SCNX Other Pharmaceuticals
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- GOVX Health Care
- Exchange
- SCNX Nasdaq
- GOVX Nasdaq
- Market Cap
- SCNX 14.4M
- GOVX 15.5M
- IPO Year
- SCNX 2020
- GOVX N/A
- Fundamental
- Price
- SCNX $0.96
- GOVX $0.95
- Analyst Decision
- SCNX
- GOVX Strong Buy
- Analyst Count
- SCNX 0
- GOVX 5
- Target Price
- SCNX N/A
- GOVX $12.40
- AVG Volume (30 Days)
- SCNX 125.4K
- GOVX 1.5M
- Earning Date
- SCNX 08-10-2025
- GOVX 08-05-2025
- Dividend Yield
- SCNX N/A
- GOVX N/A
- EPS Growth
- SCNX N/A
- GOVX N/A
- EPS
- SCNX N/A
- GOVX N/A
- Revenue
- SCNX $146,901.00
- GOVX $5,591,576.00
- Revenue This Year
- SCNX N/A
- GOVX N/A
- Revenue Next Year
- SCNX N/A
- GOVX N/A
- P/E Ratio
- SCNX N/A
- GOVX N/A
- Revenue Growth
- SCNX N/A
- GOVX N/A
- 52 Week Low
- SCNX $0.69
- GOVX $0.73
- 52 Week High
- SCNX $23.77
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- GOVX 46.22
- Support Level
- SCNX N/A
- GOVX $0.85
- Resistance Level
- SCNX N/A
- GOVX $1.39
- Average True Range (ATR)
- SCNX 0.00
- GOVX 0.15
- MACD
- SCNX 0.00
- GOVX -0.02
- Stochastic Oscillator
- SCNX 0.00
- GOVX 18.52
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.